Retinoids have shown promise in cancer prevention and therapy. As some retinoids exhibit undesirable side effects, new retinoid analogs have been synthesized. In this study, we examined the effects of the retinoid MX3350-1 on human head and neck squamous cell carcinoma (HNSCC) cell lines. MX3350-1 suppressed the growth of 7/8 HNSCC cell lines by >65%. This inhibition appeared to be due to induction of apoptosis as revealed by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. Studies with cell line UMSCC17B indicated that apoptosis was induced within 1-2 days and involved activation of caspase-8, -9, and -3. Inhibitors of these caspases suppressed MX3350-1-induced apoptosis. MX3350-1 decreased the levels of antiapoptotic Bcl-2 and Bcl-XL, increased proapoptotic Bax, induced mitochondrial membrane permeabilization (MMP), and cytochrome c release from mitochondria to cytosol. The antioxidant butylated hydroxyanisol and the MMP inhibitor cyclosporin A (Cs A) blocked apoptosis induced by MX3350-1. In contrast, retinoid receptor antagonists failed to inhibit apoptosis. MX3350-1 increased the levels of Fas-ligand, Fas, and Fas-associated death domain, and enhanced activation of procaspase-8 and cleavage of its substrate Bid. Soluble Fas rescued the cells from MX3350-1-induced apoptosis. These results demonstrate that MX3350-1 induces apoptosis by activating both extrinsic and intrinsic apoptosis pathways and suggest that further studies on the potential of this retinoid for prevention and therapy of HNSCCs are warranted.
Introduction
Retinoids, which are a class of natural and synthetic vitamin A analogs, have shown activities of cancer prevention and cancer therapy against many cell types, including normal, premalignant, or malignant head and neck cancers, both in vivo and in vitro (Lee et al., 2000; D'Ambrosio et al., 2001; Chakravarti et al., 2003) . Two types of nuclear retinoids receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), are thought to mediate retinoid signals Lotan, 2001) . These receptors usually bind as heterodimers to specific DNA sequences and/or interact with other transcriptional regulators, such as AP-1 to regulate gene transcription (Disepio et al., 1999) . However, the broad biological activities of natural retinoids may have led to a number of undesirable side effects that limited their long-term clinical use as chemopreventive agents. Therefore, new synthetic retinoids, with restricted receptor selectivity have been designed and characterized to identify those retinoids that activate only the desirable parts of the complex retinoid response network and activate selective biological programs with minimal side effects (Ulukaya and Wood, 1999; Guruswamy et al., 2001; Lotan, 2003; Pfahl and Piedrafita, 2003) .
Although many of the biological activities of retinoids are mediated by nuclear retinoid receptors (Lotan, 2003) , a group of synthetic retinoids called retinoidrelated molecules (RRMs), which is characterized by naphthotic acid and adamantyl moieties has been shown to induce apoptosis by a mechanism that is independent of the retinoid receptor pathway (Lotan, 2003; Pfahl and Piedrafita, 2003; Garattini et al., 2004) . For example, CD437 is an RARg selective retinoid, yet its proapoptotic effects are independent of retinoid receptor signaling pathway in most cancer cell types (Marchetti et al., 1999; Sun et al., 2000; Lotan, 2003) . Moreover, CD437 was found to modulate the expression of some apoptosis-related proteins (Sun et al., 1999) , caspases (Mologni et al., 1999) , and Bcl-2 family members in several types of cancers cell lines (Hsu et al., 1997) .
MX3350-1, which is a member of the RRM group of retinoids, was shown to inhibit the growth of human non-small-cell lung cancer (NSCLC) in vitro and in vivo (nude mouse xenograft model) with minimal side effects (Lu et al., 1997) . It was also reported that MX3350-1 activated c-Jun NH 2 -terminal kinase (JNK) and p38 kinase (Ortiz et al., 2001) , and inhibited IkB kinase (IKK) in vitro in a cell type-specific manner (Bayon et al., 2003) . The activation of JNK may be the result of binding of RRMs to the MAPK phosphatase-1 (MKP-1), which dephosphorylates JNK .
In the present study, we examined the ability of MX3350-1 to induce apoptosis in HNSCC cell lines and explored some aspects of the mechanism of apoptosis induction by this agent. We demonstrate that MX3350-1 induces apoptosis by activating both the mitochondrial (intrinsic) pathway and the death receptor-mediated (extrinsic) pathway via a mechanism that appears to be independent of nuclear retinoid receptors.
Results

Effect of MX3350-1 on the growth of head and neck squamous carcinoma cancer (HNSCC) cells
We examined the effects of treatment of eight HNSCC cell lines with different concentrations of the retinoid MX3350-1 (see structure in Figure 1 ) for 1, 3, and 5 days. MX3350-1 promoted a time-dependent and dosedependent inhibition of proliferation in all of the HNSCC cell lines (Figure 2 ). The UMSCC17B and SqCC/Y1 cells were very sensitive showing considerable inhibition after treatment with as low as 0.5 mM MX3350-1 (Figure 2 ). In contrast, the sensitivity of HNSCC 1483 cells was much lower than the sensitivities of the other HNSCC cell lines.
Effect of MX3350-1 on apoptosis in UMSCC17B cells
The growth inhibitory effects of MX3350-1 on the HNSCC cell lines appeared to be due to apoptosis induction as determined by the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) assay (Figure 3a ). Further studies with the UMSCC17B cells revealed that MX3350-1 induced apoptosis in a time-dependent fashion, increasing from 27% after 1 day to 98% after 3 days (Figure 3b and c) .
Effect of MX3350-1 treatment on caspase activation
Activation of individual caspases is an autocatalytic process or is triggered by other members of the caspase family in a cascade fashion. Caspase-3 is downstream of at least two pathways (extrinsic and intrinsic), which includes caspase-8 and -9. The activation of procaspases by cleavage is accompanied by the disappearance of the intact protein and the appearance of proteolytic cleavage bands corresponding to the large and small subunit of the catalytically active enzyme. To investigate whether MX3350-1 activated any of these pathways, we studied changes in the level of procaspase-8, -9 and -3 by Western blot analysis (Figure 4a ). Treatment of UMSCC17B cells with MX3350-1 for 48 h results in time-and dose-dependent activation of these three procaspases (Figure 4a , b, and c). The activation of caspase-3 was also evident by the cleavage of its substrate PARP (Figure 4b ). Specific inhibitors of caspase-8, -9, and -3 suppressed MX3350-1-induced apoptosis (Figure 4d ), whereas inhibitors of caspase-5 and -6 failed to do so (data not shown).
Effects of MX3350-1 on apoptosis induction through the mitochondrial pathway Activation of the mitochondrial pathway by MX3350-1 was indicated by the activation of procaspase-9 and by the release of cytochrome c from mitochondria 12 h after MX3350-1 exposure (Figure 4b ). Since the release of cytochrome c often involves changes in mitochondrial membrane permeabilization (MMP) (Lotan, 2003) , we then analysed whether MX3350-1 induced any changes in the fluorescence of the membrane potential sensitive dye DiOC 6 (3 0 -dihexyoxacarbocyanine iodide), which is indicative of MMP (Lotan, 2003) . Figure 5a shows that MX3350-1 increased the percentage of cells with low This effect was suppressed in the presence of cyclosporin A (Cs A), an inhibitor of MMP (Marchetti et al., 1999) . Cs A was also able to efficiently suppress the apoptosis induced by MX3350-1 treatment (Figure 5b) . Likewise, the antioxidant butylated hydroxyanisol (BHA) suppressed apoptosis induction by MX3350-1 (Figure 5b ), suggesting a role for oxygen radicals in the effect of MX3350-1. Several members of the Bcl-2 family can regulate MMP and the release of cytochrome c from mitochondria. For example, Bcl-2 and Bcl-xL can inhibit these processes, whereas Bax can stimulate them (Gross et al., 1999) . We found a decrease in the level of Bcl-2 and BclxL in UMSCC17B cells after a 48-h treatment with MX3350-1 (Figure 5c ). In contrast, the level of the cleaved form of Bax, which is more potent than the intact proapoptotic member Bax, was found to increase after MX3350-1 exposure ( Figure 5c ). death receptor (e.g. Fas) and this is followed by receptor clustering and transmission of a signal via interactions of the cytoplasmic death domains of the receptors with adaptor proteins (e.g. Fas-associated death domain (FADD)) that activate procaspase-8 (Nagata and Golstein, 1995; Dragovich et al., 1998; Strasser and Newton, 1999; Bang et al., 2000; Schmitz et al., 2000) . Caspase-8 can then activate procaspase-3 and also cleave Bid to form truncated Bid (tBid), which translocates to the mitochondrial membrane and enhances cytochrome c release (Tang et al., 2000; Yin, 2000) . To determine whether MX3350-1 affects the death receptor apoptosis pathway, we analysed the effects of this retinoid on FasL, Fas, FADD, caspase-8, and Bid in UMSCC17B cells by Western blotting. The results shown in Figure 6a demonstrate increased levels of FasL, Fas, FADD, and caspase-8 in a timedependent manner beginning 6-12 h after exposing the cells to MX3350-1. The increase in these proteins levels off between 24 and 48 h after treatment initiation. The level of Bid decreased concurrently with the above changes, presumably as a result of truncation by caspase-8. These results indicate that MX3350-1 increased the levels of both FasL and Fas, which could interact and initiate death signaling. To further test this possibility, we examined the ability of soluble Fas (sFas) to interfere with MX3350-1-induced apoptosis by competing with membrane-associated Fas for the ligand FasL. Figure 6b shows that MX3350-1 is ineffective in inducing apoptosis of HNSCC17B cells, if the cells are pretreated with sFas for 2 h followed by concurrent treatment with MX3350-1 and sFas.
Effects of RAR and RXR antagonist and agonist on induction of apoptosis by MX3350-1 in UMSCC17B cells
Since MX3350-1 can activate RARg preferentially, we asked whether retinoid receptors mediate its proapop- Cells were treated with 2 mM MX3350-1 for the indicated times, harvested, and analysed by Western blotting for evidence of cytochrome c release from the mitochondria fraction in the pellet (P) to cytosol fraction in supernatant (S) and for activation of caspase-9 and -3 and cleavage of the caspase-3 substrate PARP as described in 'Materials and methods'. (c) Cells were treated with 2 mM MX3350-1 for the indicated times and harvested and processed for analysis of caspase-3-like enzymatic activity as described in 'Materials and methods'. The results were calculated as the mean7s.e.m. of triplicate assays; however, the error bars were too small to be visible in the graph. (d) Cells were treated for 1 day with 2 mM MX3350-1 alone or the caspase-3, -8, or -9 inhibitors (see Materials and methods) each alone or the combinations of MX3350-1 and each of the caspase inhibitors and then they were harvested and analysed for apoptosis by the TUNEL assay. Cells treated with DMSO were used as control totic effects. First we examined the effects of the combination of MX3350-1 and the RXR agonist SR11234 because receptors regulate gene expression by binding to gene promoter sequences as RAR-RXR heterodimers and combinations of an RAR ligand (e.g. MX3350-1) and an RXR ligand would be expected to have additive or synergistic effect (Lotan et al., 1995; Nagy et al., 1995) . SR11234 alone caused less than 10% apoptosis and its combination with MX3350-1 did not result in greater apoptosis than that observed with MX3350-1 alone (Figure 7) . Another approach to test the role of retinoid receptors was to examine the effects of cotreatment of the UMSCC17B cells with combinations of MX3350-1 and either an RAR antagonist (AGN193109) or RXR antagonist (LG100754). Neither AGN193109 nor LG100754, both at 20 mM, were able to rescue the HNSCC cells from apoptosis induction by MX3350-1 (Figure 7 ). These findings were in contrast with our observation that both antagonists rescued HNSCC cells from apoptosis induction by all-trans retinoic acid or 9-cis retinoic acid (data not shown).
Discussion
MX3350-1, a synthetic retinoid originally characterized as a selective RARg agonist, was reported to exhibit antitumor activity both in vitro in human breast, lung, and head and neck cancer cells and in vivo in human lung cancer xenografts in a nude mouse model without significant side effects or toxicity (Lu et al., 1997). Immunoblotting of the same membranes with antibodies to b actin was used to control for loading. (b) Cells were treated with 5 mg/ml soluble Fas (sFas) for 2 h, then MX3350-1 (2 mM) was added and the cells were incubated for an additional 48 h. The cells were then harvested and analysed for apoptosis by the TUNEL assay as described in 'Materials and methods'. The results represent one of two experiments, which yielded similar results MX3350-1 induces apoptosis in several cancer cell lines; however, the mechanism by which it exerts its effects is only beginning to be unraveled. Specifically, MX3350-1 was found to activate caspase-3, -6, -7, -8, and -9 in human acute leukemia Jurkat T cells (Ortiz et al., 2001) . Furthermore, MX3350-1 activated JNK and stressassociated protein kinase (SAPK)/p38 and inhibitors of these kinases blocked caspase 3 activation (Ortiz et al., 2001) .
In the present study, we examined the effects of MX3350-1 on several HNSCC cell lines and found that they were all sensitive to the growth inhibitory effects of MX3350-1, albeit to different degrees, and that the effects correlated with apoptosis induction. We then examined various aspects of the mechanisms of apoptosis induction by MX3350-1 in UMSCC17B cells, which are resistant to all-trans retinoic acid but sensitive to MX3350-1. The initial effect of MX3350-1 (o24 h) was growth inhibition (69%) due to G1 arrest. Apoptosis induction by MX3350-1 was only 27% at this time. However, after 24 h of treatment, apoptosis increased reaching 75% after 48 h and over 95% at 72 h as evidenced by the TUNEL assay. The mechanism by which MX3350-1 induces apoptosis appears to be independent of nuclear retinoid receptors as indicated by the failure of the pan-RAR antagonist AGN193109 and the RXR antagonist LGD100754 to inhibit MX3350-1-induced apoptosis.
MX3350-1 activated caspase-3 -8, and -9. These results support the conclusion that both the mitochondrial and the death receptor pathways are activated by MX3350-1.
The activation of caspase-9 is characteristic of the mitochondrial apoptosis pathway (intrinsic pathway). We found further support that MX3350-1 activated this pathway by showing that suppression of MMP with Cs A rescued the cells from MX3350-1-induced apoptosis. The mechanism by which MX3350-1 affects the mitochondrial membrane is still unknown. However, because MX3350-1 can activate JNK (Ortiz et al., 2001) , it may act by the mechanism that had been described for stress-inducing agents (e.g. UV radiation, anisomycin, chemotherapeutic agents), which invoke the intrinsic apoptotic pathway via JNK activation (Krilleke et al., 2003) . Bcl-2 and its family member proteins including Bcl-xL, tBid, and Bax are important regulators of cytochrome c release from mitochondria (Daniel et al., 2003) . They are thought to interact with voltagedependent anion channel (VDAC) and/or adenine nucleotide transporter (ANT) to regulate the opening of mitochondrial membrane permeability transition pores (PTPs) during apoptosis to allow various regulators of apoptosis to be released into the cytosol (e.g. cytochrome c) (Kroemer, 1997; Shimizu et al., 1999; Daniel et al., 2003) . Both Bax and Bcl-xL interact with VDAC to form a complex that can mediate cytochrome c release depending on the ratio between Bax and Bcl-xL (Shi et al., 2003) . Interestingly, we found that MX3350-1 decreased the levels of the antiapoptotic proteins Bcl-2 and Bcl-xL. In addition, MX3350-1 induced a cleavage of p21 Bax to p18 Bax probably due to calpain-induced cleavage. Such a cleavage is known to occur during and enhance the process of stress-induced apoptosis (Yanase et al., 2000; Cao et al., 2003) .
Our results also demonstrate that MX3350-1 activates a second apoptosis pathway emanating from cell surface death receptors (extrinsic pathway). The death receptor Fas/CD95 can be activated to undergo oligomerization by binding its ligand FasL (Nagata and Golstein, 1995; Dragovich et al., 1998; Schmitz et al., 2000) . The activated Fas then recruits an adaptor molecule, the FADD, and procaspase-8 into a complex resulting in activated caspase-8 (Strasser and Newton, 1999; Bang et al., 2000) . This caspase can in turn activate procaspase-3 (Tang et al., 2000) . In addition, it can cleave the Bcl-2 family member Bid to form tBid, which can translocate to the mitochondria and enhance cytochrome c release (Yin, 2000) . We found that MX3350-1 increased considerably the levels of Fas, FADD, and activated caspase-8 within 6-12 h, with a decline in intact Bid occurring concurrently with caspase-8 activation. These changes are very likely related causally to the induction of apoptosis. In contrast, FasL is expressed constitutively and shows only a modest increase in FasL after 12 h followed by a more pronounced increase after 48 h. Although the increase in FasL appears to be less important, the constitutive FasL is important for the induction of apoptosis by MX3350-1 as evidenced by the ability of soluble Fas to suppress this apoptosis. We examined the mechanism of apoptosis induction by MX3350-1 only in HNSCC cell lines, therefore, we do not know whether this is a general mechanism that applies also to other cancer cell types as well. It is noteworthy, however, that a related retinoid CD437 has been shown to increase the level of Fas and other death receptors (DR4 and DR5) in lung cancer cells (Sun et al., 1999 (Sun et al., , 2000a .
In conclusion, our results demonstrated that MX3350-1 is a potent inducer of apoptosis with a unique mechanism of action depicted schematically in Figure 8 . MX3350-1 increases MMP possibly by decreasing the levels of Bcl-2 and Bcl-xL and increasing Bax and its cleaved activated form and tBid. This leads to cytochrome c release from mitochondria and activation of caspase-9 and -3 resulting in PARP cleavage and apoptosis. In addition, MX3350-1 also activates the cell death receptor pathway by increasing both Fas and FADD, resulting in activation of caspase-8 and -3 and triggering an autocrine suicide loop in the HNSCC cells.
Materials and methods
Retinoids
The pan-RAR antagonist AGN193109 was provided by Allergen (Irvine, CA, USA). The RXR-selective retinoid SR11234 was provided by Dr MI Dawson (The Burnham Institute, San Diego, CA, USA). The RXR antagonist LG100754 was provided by Ligand Pharmaceuticals, Inc. (San Diego, CA, USA). They have been used at the doses determined previously to antagonize receptor activation (Sun et al., 2000b) .
Cell lines and cell culture
Human HNSCC cell lines UMSCC10B, UMSCC14B, UMSCC17B, UMSCC22B, and UMSCC38 were obtained from Dr T Carey (University of Michigan, Ann Arbor, MI, USA). HNSCC cell lines 183A and 1483 were provided by Dr PG Sacks (New York University College of Dentistry, New York, NY, USA). SqCC/Y1 cells were provided by Dr M Reiss (Yale University, New Haven, CT, USA). The cells were grown in monolayer culture in a 1 : 1 (V/V) mixture of Dulbecco's modified Eagle's minimum essential medium (DMEM) and Ham's F12 medium and supplemented with 5% fetal bovine serum and antibiotics at 371C in a humidified atmosphere consisting of 95% air and 5% CO 2 .
Treatment with MX3350-1 and determination of cell growth
Cells were seeded at a density 3000 cells per well in 96-well tissue culture plates. After 24 h, cells were treated with different concentrations of MX3350-1. Control cultures received the same amount of DMSO (0.01-0.1%), as did the treated cultures. On indicated days, cell numbers were estimated by using the Sulforhodamine B (SRB) assay as described previously (Chun et al., 2003b) .
Detection of apoptosis
UMSCC17B cells were plated on 10-cm-diameter dishes, and, after 24 h, they received either DMSO or retinoids dissolved in DMSO. After 1, 2, and 3 days of treatment, cells were harvested by a brief trypsinization and counted. APO-DIRECT TUNEL kit (Phoenix Flow Systems, Inc., San Diego, CA, USA) was used following the manufacturer's protocol to label DNA fragments at the 3 0 -hydroxyl ends. Flow cytometric analysis was conducted using a Coulter EPICS Profile II flow cytometer (Coulter Corp., Miami, FL, USA). Approximately 10 000 events (cells) were evaluated for each sample.
Assay for detection of MMP
MMP was evaluated using the membrane potential-sensitive dye DiOC 6 as described previously (Chun et al., 2003a) . Briefly, after treatment of the 17B cells with MX3350-1, the floating cells were combined with cells detached by trypsinization and then incubated with 50 nM DiOC 6 for 15 min at 371C. The uncoupler protonophore CCCP (carbonyl cyanide m-chlorophenylhydrazone) (50 mM), which disrupts transmembrane potential, was used as a positive control. The cells were then analysed using a cytofluorimeter (Facscalibar, excitation at 488 nm: emission at 552 nm). At least 10 000 events were collected per sample. The suppression of MMP is represented as a shift of the fluorescence peak to lower levels and the percentage of cells in the lower fluorescence category was calculated and plotted in the graphs.
Detection of proteins by Western blotting
Cytochrome c release was detected as described previously (Chun et al., 2003a) . The MX3350-1-treated cells were disrupted by homogenization on ice in Kontes dounce homogenizer (Kontes Glass Company) with 40 strokes of B pestle. The homogenate was subjected to centrifugation, the supernatant (called cytosolic extract) and the pellet (called mitochondria extract) and affinity-purified anti-cytochrome c antibody 7H8.22C12 (Pharmingen, San Diego, CA, USA) were used for Western blotting. The following antibodies were used: caspase-1 p10 (C-20), Bcl-2 (100), Bcl-xL (H-62), FasL 
